Brief: Resverlogix receives approval pathway from the FDA as to the inclusion of USA patients in the phase 3 betonmace trial

Resverlogix

25/07/2017 14:00

July 25 (Reuters) - Resverlogix Corp  RVX.TO : 
    * Resverlogix receives approval pathway from the FDA as to 
the inclusion of usa patients in the phase 3 betonmace trial 
    * Resverlogix Corp - receipt of a positive type c written 
response from division of metabolism and endocrinology products 
of U.S. FDA 
    * Resverlogix Corp- agreed to make adjustments to existing 
betonmace study protocol and to update investigator's brochure 
and informed consent documents 
    * Resverlogix-FDA approval to proceed with phase 3 betonmace 
trial in USA well timed, should not have major impact on total 
duration of betonmace trial 
 
Source text for Eikon:  ID:nCNWJSz8la  
Further company coverage:  RVX.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com;))